CAR.B7-H3

Phase 1Small molecule

UUNC Lineberger Comprehensive Cancer Center

CAR.B7-H3 is one of 3 small molecule programs targeting Recurrent Epithelial Ovarian. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Epithelial OvarianActive, not recruiting

Recurrent Epithelial OvarianPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Recurrent Epithelial Ovarian

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 1

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 3

CAR.B7-H3

UUNC Lineberger Comprehensive Cancer Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1Active, not recruiting

Recurrent Epithelial Ovarian

NCT04670068

Clinical

Trials by Indication[1]

Recurrent Epithelial Ovarian1 trial

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT04670068·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CAR.B7-H3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR.B7-H3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR.B7-H3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUNC Lineberger Comprehensive Cancer Center

CAR.B7-H3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Recurrent Epithelial Ovarian1 trial

References

Drug Info

Quick Facts

Related News